Learning pointsDifferent mechanisms could lead to dabigatran failure in non-valvular atrial fibrillation, despite adequate dosing, good therapeutic adherence, and the absence of concomitant interacting drugs.Off-label treatment with idarucizumab makes intravenous thrombolysis safe and effective in case of dabigatran failure.

Introduction
============

Atrial fibrillation (AF) is a well-known risk factor for stroke or systemic embolism, frequently associated with left atrial appendage (LAA) or left atrial (LA) thrombi. For decades, vitamin K antagonists (VKAs) have been the mainstay of stroke prevention in AF patients. Dabigatran etexilate is a direct, competitive, and reversible thrombin inhibitor, licensed for prevention of stroke/systemic embolism in non-valvular AF (NVAF). At 150 mg b.i.d., dabigatran showed similar rates of bleedings and higher efficacy compared to warfarin.[@ytaa057-B1] Idarucizumab, a humanized monoclonal antibody fragment, reverses the anticoagulant effect of dabigatran within minutes and seems to be promising for rapid reversal of dabigatran effects, even before rt-PA.[@ytaa057-B2]^,^[@ytaa057-B3] In case of dabigatran failure, a thorough investigation is warranted to identify the aetiological diagnosis of stroke and redefine the secondary prevention strategy. Here, we report the case of a dabigatran-treated patient presenting with acute stroke, who underwent idarucizumab followed by intravenous thrombolysis (IVT) and was subsequently diagnosed a large LAA thrombus. We reviewed the literature and tried to analyse the potential mechanisms underlying LAA or LA formation during dabigatran treatment.

Timeline
========

  ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Past history and medication at baseline   Non-valvular atrial fibrillation, hypertension, Type 2 diabetes mellitus, hypercolesterolaemia. Dabigatran 150 mg b.i.d., metformin, telmisartan, furosemide, atenolol, rosuvastatin, ezetimibe, and doxazosine.
  Emergent assessment and treatment         Clinical features of total left anterior circulation syndrome (National Institute of Health Stroke Scale, NIHSS 21). Computed tomography scan shows distal left M1 occlusion. Off-label treatment with idarucizumab 5 g IV as a bolus, followed by IV rt-PA 0.9 mg/kg at 2 h from symptoms onset.
  Aetiopathogenetic diagnostic work up      Transoesophageal echocardiography (TOE) reveals a left atrial appendage (LAA) thrombus.
  Condition and treatment at discharge      No haemorrhagic complications after intravenous thrombolysis. At discharge, mild reduction in verbal fluency (NIHSS 2). Dabigatran is interrupted and warfarin is started.
  3 months follow-up                        Independent patient (modified Rankin scale 1), with a good time-to-range. Complete resolution of her LAA thrombus at TOE.
  ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Case presentation
=================

Patient information
-------------------

A 73-year-old woman presented to our emergency department an hour after the acute onset of a total left anterior circulation syndrome, with right-sided hemiplegia, global aphasia, right-sided hemianopsia, forced left-sided eye deviation, and National Institute of Health Stroke Scale (NIHSS) score 21. Her past medical history, reported by her husband, was remarkable for diabetes, hypercholesterolaemia, hypertension, and permanent NVAF, treated with warfarin for many years. A year before, she was switched to dabigatran 150 mg b.i.d. for its more manageable profile. Last dabigatran intake was 10 h before stroke onset. The patient was also on metformin, telmisartan, furosemide, atenolol, rosuvastatin, ezetimibe, and doxazosin.

Diagnostic assessment
---------------------

The electrocardiogram showed AF with a ventricular response of 80 b.p.m. Coagulation studies revealed activated partial thromboplastin time (aPTT) ratio 1.6, prothrombin time (PT) ratio 1.24. An ecarin clotting time (ECT) could not be performed. The brain computed tomography angio showed an occlusion of left middle cerebral artery (*[Figure 1](#ytaa057-F1){ref-type="fig"}*), according to her clinical deficits.

![Computed tomography angio showing left middle cerebral artery occlusion.](ytaa057f1){#ytaa057-F1}

Interventions
-------------

She was off-label treated with idarucizumab 5 g IV as a bolus, followed by IV rt-PA 0.9 mg/kg at 2 h from symptoms onset and directly transferred to cath lab for mechanical thrombectomy. The diagnostic angiography revealed complete middle cerebral artery recanalization by the end of IVT (*[Figure 2](#ytaa057-F2){ref-type="fig"}*).

![Digital subtraction angiography showing complete recanalization of left middle cerebral artery, by the end of intravenous thrombolysis with rt-PA.](ytaa057f2){#ytaa057-F2}

The patient experienced no haemorrhagic complications. The neurological conditions progressively improved, with the exception of mild reduction in verbal fluency, NIHSS score 2. She underwent a thorough cardiological investigation and a large thrombus in the LAA was demonstrated at the transoesophageal echocardiography (*[Figure 3](#ytaa057-F3){ref-type="fig"}*). The patient refused LAA closure and warfarin was started. At 3 months, she was independent with a modified Rankin scale 1, with a good interantional normalized ratio (INR) time-to-range. A follow-up echocardiography showed the complete resolution of her LAA thrombus.

![Transoesophageal echocardiography showing a large left atrial appendage thrombus.](ytaa057f3){#ytaa057-F3}

Discussion
==========

Since its approval in 2010, dabigatran has been an effective alternative to VKAs, reducing the primary outcome of stroke/systemic embolism by 34% compared to warfarin in the RE-LY trial.[@ytaa057-B1] However, during dabigatran treatment, LAA or LA thrombi formation were reported. Five out of 10 patients were on low-dose dabigatran, at the time of diagnosis.[@ytaa057-B4] Two out of 10 patients were on full-dose dabigatran. One of them was simultaneously taking phenytoin.[@ytaa057-B9] In another case, an LAA thrombus persisted despite warfarin and full-dose dabigatran.[@ytaa057-B10] One out of 10 patient was on dabigatran, despite valvular AF.[@ytaa057-B11] Of the last two patients, one was also affected by lung cancer.[@ytaa057-B12]

No certain mechanisms for dabigatran failure have been identified, but several theories have been proposed.[@ytaa057-B4]^,^[@ytaa057-B8] Firstly, inadequate dosing seems to be the most common cause for dabigatran failure. Secondly, single level downstream inhibition of thrombin may lead to compensatory increase in upstream clotting factors. Thirdly, all the available thrombin may not be inhibited. Fourthly, absence of monitoring may hamper assessment of therapeutic adherence and anticoagulation status. Moreover, due to its short half-life, dabigatran may possibly cause an hourly variation of anticoagulation level. Finally, a genetic susceptibility may be present, involving the ABCB1 and CES-1 genes. The former encodes for P-glycoprotein (P-gp), one of the drug transporters in the gastrointestinal and urinary tracts. Particular ABCB1 haplotypes may result in 5% lower trough concentration of dabigatran. CES-1 gene encodes for the liver carboxylesterase 1 enzyme and it is responsible for the biotransformation of dabigatran etexilate into its active metabolite. Patients carrying particular alleles showed up to 28% decrease in adjusted peak concentration. Interestingly, the frequency of these genetic haplotypes may be present in up to one-third of overall population.[@ytaa057-B13]^,^[@ytaa057-B14]

Knowledge regarding drugs interacting with dabigatran is expanding.[@ytaa057-B15] The main mechanism involved is at P-gp level. Competitive inhibitors of P-gp result in increased dabigatran plasma levels, through gastrointestinal re-secretion. Among them, verapamil, quinidine, dronedarone, and amiodarone are frequently used for AF. Significant reduction of dabigatran plasma levels is known for P-gp inducers, such as rifampicin, dexamethasone, as well as several antiepileptic and anticancer drugs. The concomitant use of proton pump inhibitors and H2-blockers leads to a small reduction in bioavailability of dabigatran, apparently without clinically relevant effects.

In dabigatran-treated patients, aPTT only provides a qualitative assessment of anticoagulant activity: aPTT in the normal range in fact only rules out supra-therapeutic dabigatran levels. For a quantitative assessment, diluted thrombin time (dTT) and ECT are recommended.[@ytaa057-B15] The limitation of our case report is that we were not able to quantitatively measure dabigatran anticoagulant activity due to the absence of dTT and ECT in our laboratory.

Conclusion
==========

In our case, we confirmed initial reports of safety of IVT after idarucizumab, in case of dabigatran failure. In our case, IVT treatment resulted in complete arterial recanalization. We also demonstrated the presence of an LAA thrombus despite adequate dosing, good therapeutic adherence, and the absence of concomitant interacting drugs. We suggest that individual variations in anticoagulation status may possibly account for drug failure. Thus, periodical assessment of dabigatran anticoagulant levels, by dTT or ECT assessment, may thus be warranted.
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